Feb. 24 at 3:46 PM
$IVVD -Doom & Gloom report on IVVD- Don’t Fight the Anti-Vaccine Market — Serve It.
Invivyd has an approved monoclonal antibody, PEMGARDA (pemivibart), authorized under EUA for pre-exposure prophylaxis of COVID-19 in moderately to severely immunocompromised individuals. PEMGARDA binds a highly conserved epitope on the SARS-CoV-2 spike protein that has remained intact across all clinically relevant variants tested to date. The drug is administered intravenously approximately every three months and represents a specialty prophylaxis product rather than a mass-market therapy.
Clinically, PEMGARDA demonstrated strong efficacy in the randomized CANOPY trial. At 90 days, symptomatic, RT-PCR–confirmed COVID occurred in 0.3% (1/317) of treated patients versus 5.0% (8/160) in placebo, corresponding to a 93.7% relative risk reduction (p=0.009). This result validates both the epitope selection and the monoclonal antibody approach.
(Source: https://academic.oup.com/cid/article/81/3/439/8145246?login=false )
